Ocrelizumab
CNS Demyelinating Autoimmune Disease
Explore 6 assets in CNS Demyelinating Autoimmune Disease →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Indapta Therapeutics, INC.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06677710CT.gov IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · CNS Demyelinating Autoimmune Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ocrelizumab (this asset) | Indapta Therapeutics, INC. | P1 | CC · 43 |
| Idp-023 | Indapta Therapeutics, INC. | P1 | CC |
| Cyclophosphamide | Indapta Therapeutics, INC. | P1 | CC |
| Fludarabine | Indapta Therapeutics, INC. | P1 | CC |
| Mesna | Indapta Therapeutics, INC. | P1 | CC |
| Natalizumab | Queen Mary University of London | P2 | NR |
Other indications for Ocrelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 76 |
| Primary Progressive Multiple Sclerosis | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ocrelizumab in CNS Demyelinating Autoimmune Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ocrelizumab-cns-demyelinating-autoimmune-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →